Sept 7 2016 NOX66 and Radiotherapy by Dr Graham Kelly

Posted on September 7th, 2016 by Blog Author

In a recent ASX announcement, we made mention of opening up a second clinical front for NOX66, that being to use it in conjunction with radiotherapy.   Our objective is to open up two Phase 1 studies of NOX66 + radiotherapy over the next 6 months. These will complement the NOX66 + chemotherapy study we […]

Read More

5-Sep-2016: NOX66 Technology Explained by Dr Graham Kelly

Posted on September 5th, 2016 by Blog Author

SEPTEMBER 5, 2016:   NOX66 TECHNOLOGY EXPLAINED       by Dr Graham Kelly   Here is an obvious question: Idronoxil was tested in over 400 cancer patients over a 10-year period. In the end, it didn’t work in enough patients to warrant the investment to continue to bring it to market. So why do we think we can […]

Read More